CoChat

Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer

Saylor, Philip J., Smith, Matthew R. · 2013 · Journal of Urology
Cited by 137

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

No AccessJournal of UrologyOncology: Prostate/Testis/Penis/Urethra1 Jan 2013Metabolic Complications of Androgen Deprivation Therapy for Prostate Canceris accompanied byMetabolic Complications of Androgen Deprivation Therapy for Prostate Cancer Philip J. Saylor and Matthew R. Smith Philip J. SaylorPhilip J. Saylor and Matthew R. SmithMatthew R. Smith View All Author Informationhttps://doi.org/10.1016/j.juro.2012.11.017AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: Androgen deprivation therapy has a variety of well recognized adverse effects including vasomotor flushing, loss of libido, fatigue, gynecomastia, anemia and osteoporosis. This review focuses on the more recently described metabolic complications of androgen deprivation therapy including obesity, insulin resistance and lipid alterations as well as the association of androgen deprivation therapy with diabetes and cardiovascular disease. Materials and Methods: We reviewed the medical literature using the PubMed® search terms prostate cancer, androgen deprivation therapy, gonadotropin-releasing hormone agonists, obesity, insulin resistance, lipids, diabetes, cardiovascular disease and myocardial infarction. We provide a focused review and our perspective on the relevant literature. Results: Androgen deprivation therapy decreases lean mass and increases fat mass. It also decreases insulin sensitivity while increasing low density lipoprotein cholesterol, high density lipoprotein cholesterol and triglycerides. Consistent with these adverse metabolic effects, androgen deprivation therapy may be associated with a greater incidence of diabetes and cardiovascular disease. Some of these androgen deprivation therapy related metabolic changes (obesity, insulin resistance and increased triglycerides) overlap with features of the metabolic syndrome. However, in contrast to the metabolic syndrome, androgen deprivation therapy increases subcutaneous fat and high density lipoprotein cholesterol. Conclusions: Androgen deprivation therapy increases obesity, decreases insulin sensitivity and adversely alters lipid profiles. It may be associated with a greater incidence of diabetes and cardiovascular disease. The benefits of androgen deprivation therapy should be weighed against these and other potential harms. Little is known about the optimal strategy to mitigate the adverse metabolic effects of androgen deprivation therapy. Thus, we recommend an emphasis on existing strategies for screening and treatment that have been documented to reduce the risk of diabetes and cardiovascular disease in the general population. References 1 : Stat Fact Sheets: Prostate Cancer. : 2008. Google Scholar 2 : Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med1997; 337: 295. Crossref, Medline, Google Scholar 3 : 6-Month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA2004; 292: 821. Google Scholar 4 : Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial: The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol1997; 158: 1623. Google Scholar 5 : The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study. BJU Int2006; 98: 973. Google Scholar 6 : Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer2005; 103: 1615. Google Scholar 7 : Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol2006; 7: 472. Google Scholar 8 : Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA2008; 300: 173. Google Scholar 9 : Obesity and diabetes in the developing world–a growing challenge. N Engl J Med2007; 356: 213. Google Scholar 10 : Update on obesity. J Clin Endocrinol Metab2008; 93: 2027. Google Scholar 11 : Testosterone, body composition and aging. J Endocrinol Invest1999; 22: 110. Google Scholar 12 : Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J Clin Endocrinol Metab2000; 85: 60. Google Scholar 13 : Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab1999; 84: 2647. Google Scholar 14 : Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. J Urol2002; 167: 2361. Link, Google Scholar 15 : Changes in body composition during andro

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.juro.2012.11.017

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 137

Metadata

Authors
Saylor, P. J., & Smith, M. R.
Venue
Journal of Urology
Published
2013-01
Volume
189
Issue
1S
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W4231246543
Cited by
137
References
17
FWCI
11.15
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer. https://app.cochat.ai/papers/10.1016/j.juro.2012.11.017
The paper
Saylor, P. J., & Smith, M. R. (2013). Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer. Journal of Urology. https://doi.org/10.1016/j.juro.2012.11.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.